Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP002 study results.
Dan is delighted to remind us of what the NXP002 programme is and its purpose, take us through the key findings and explains the next steps following the success achieved.
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing.
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.
